Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Oscar Arias-Carrión is active.

Publication


Featured researches published by Oscar Arias-Carrión.


Journal of Neuroscience Research | 2004

Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions

Oscar Arias-Carrión; Leticia Verdugo-Díaz; Alfredo Feria-Velasco; Diana Millán-Aldaco; A.A. Gutiérrez; Arturo Hernández-Cruz; René Drucker-Colín

Neurogenesis continues at least in two regions of the mammalian adult brain, the subventricular zone (SVZ) and the subgranular zone in hippocampal dentate gyrus. Neurogenesis in these regions is subjected to physiological regulation and can be modified by pharmacological and pathological events. Here we report the induction of neurogenesis in the SVZ and the differentiation after nigrostriatal pathway lesion along with transcranial magnetic field stimulation (TMFS) in adult rats. Significant numbers of proliferating cells demonstrated by bromodeoxyuridine‐positive reaction colocalized with the neuronal marker NeuN were detected bilaterally in the SVZ, and several of these cells also expressed tyrosine hydroxylase. Transplanted chromaffin cells into lesioned animals also induced bilateral appearance of subependymal cells. These results show for the first time that unilateral lesion, transplant, and/or TMFS induce neurogenesis in the SVZ of rats and also that TMFS prevents the motor alterations induced by the lesion.


Cns & Neurological Disorders-drug Targets | 2014

Effects of exercise on anxiety and depression disorders: Review of meta-analyses and neurobiological mechanisms

Mirko Wegner; Ingo Helmich; Sergio Machado; Antonio Egidio Nardi; Oscar Arias-Carrión; Henning Budde

Anxiety and depression are the most frequently diagnosed psychological diseases showing a high co-morbidity. They have a severe impact on the lives of the persons concerned. Many meta-analytical studies suggested a positive anxiolytic and depression-reducing effect of exercise programs. The aim of the present article is to synthesize metaanalyses on the effects of exercise on anxiety and depression and to describe average effect sizes. For this purpose 37 meta-analyses were included reporting 50 effect sizes for anxiety scores of 42,264 participants and depression scores of 48,207 persons. The average documented anxiolytic effect of exercise in these reviews was small, 0.34. In contrast, the effect of exercise on depression was significantly higher and at a moderate level, 0.56. Data of randomized controlled trials suggest higher sizes for the effect of exercise on anxiety and depression leading to increases up to moderate and large effects, respectively. Additionally, exercise seems to be more beneficial for patients compared to participants within a non-clinical, normal range of psychological disease. Especially for the effect of exercise on anxiety, more high quality meta-analyses of randomized controlled trials are needed. Finally, possible neurobiological explanations are suggested for the positive effect of exercise on psychological disorders like anxiety and depression.


Clinical Practice & Epidemiology in Mental Health | 2013

Epidemiology of early-onset dementia: a review of the literature

Renata Teles Vieira; Leonardo Caixeta; Sergio Machado; Adriana Cardoso Silva; Antonio Egidio Nardi; Oscar Arias-Carrión; Mauro Giovanni Carta

Presenile Dementia or Early Onset Dementia (EOD) is a public health problem, it differs from Senile Dementia, and encloses a significant number of cases; nevertheless, it is still poorly understood and underdiagnosed. This study aims to review the prevalence and etiology of EOD, comparing EOD with Senile Dementia, as well as to show the main causes of EOD and their prevalence in population and non-population based studies. The computer-supported search used the following databases: Pubmed/Medline, ISI Web of Knowledge and Scielo. The search terms were alcohol-associated dementia, Alzheimer’s disease, dementia, Creutzfeldt-jakob disease, dementia with lewy bodies, early onset dementia, frontotemporal lobar degeneration, Huntington’s disease, mixed dementia, neurodegenerative disorders, Parkinson’s disease dementia, presenile dementia, traumatic brain injury, vascular dementia. Only papers published in English and conducted from 1985 up to 2012 were preferentially reviewed. Neurodegenerative diseases are the most common etiologies seen in EOD. Among the general population, the prevalence of EOD was found to range between 0 to 700 per 100.000 habitants in groups of 25-64 years old, with an increasing incidence with age. The progression of EOD was found to range between 8.3 to 22.8 new cases per 100.000 in those aged under 65 years. Alzheimers disease (AD) is the major etiology, followed by Vascular Dementia (VaD) and Frontotemporal Lobar Degeneration (FTLD). A larger number of epidemiological studies to elucidate how environmental issues contribute to EOD are necessary, thus, we can collaborate in the planning and prevention of services toward dementia patients.


Brain | 2010

Rational therapeutic approaches to progressive supranuclear palsy

Maria Stamelou; Rohan de Silva; Oscar Arias-Carrión; Evangelia Boura; Matthias Höllerhage; Wolfgang H. Oertel; Ulrich Müller; Günter U. Höglinger

Progressive supranuclear palsy is a sporadic and progressive neurodegenerative disease, most often presenting as a symmetric, akinetic-rigid syndrome with postural instability, vertical supranuclear gaze palsy and frontal lobe deficits. It belongs to the family of tauopathies and involves both cortical and subcortical structures. Although the exact pathophysiology is not yet fully understood, several lines of evidence point to a crucial contribution from both genetic predisposition and mitochondrial dysfunction. Recently gained insights into the pathophysiology of this disease have led to several hypothesis-driven therapeutic approaches aiming at disease-modification rather than mere symptomatic neurotransmitter-replacement therapy. Agents targeting mitochondrial dysfunction have already shown a positive effect in a phase II study and further studies to verify and expand these results are ongoing. Clinical studies with agents targeting tau dysfunction such as tau-kinase inhibitors, tau-aggregation inhibitors and microtubule stabilizers are in preparation or ongoing. This review presents the current pathophysiological concepts driving these exciting therapeutic developments.


Cns & Neurological Disorders-drug Targets | 2009

Mechanisms of sleep-wake cycle modulation.

Eric Murillo-Rodríguez; Oscar Arias-Carrión; Katya Sanguino-Rodriguez; Mauricio Gonzalez-Arias; Reyes Haro

Regulation of the sleep-waking cycle is complex, involving multiple neurological circuits and diverse endogenous molecules. Interplay among assorted neuroanatomical and neurochemical systems such as acetylcholine, dopamine, noradrenaline, serotonin, histamine, and hypocretin maintain the waking (W) state. The sleep-onset is governed by the interacting forces of the sleep drive, which steadily increases with duration of W, and circadian fluctuations. Sleep-promoting neurons located in the anterior hypothalamus release GABA and inhibit wake-promoting regions in the hypothalamus and brainstem and participate in the generation of slow wave sleep (SWS). During rapid eye movement (REM) sleep, brainstem regions typically inhibited during W and SWS become active. In this regard, ascending projections from cholinergic neurons in the brainstem activate the thalamus which in turn increases the firing of the neurons in the cortex. Finally, sleep-promoting substances that accumulate in the brain during natural or prolonged W implicate a further complexity in the mechanism of modulation of the sleep-wake cycle. This review provides a broad understanding of our present knowledge in the field of sleep research.


Journal of Neurochemistry | 2011

Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson’s disease

Thomas Carlsson; Friederike R. Schindler; Matthias Höllerhage; Candan Depboylu; Oscar Arias-Carrión; Stefan Schnurrbusch; Thomas W. Rösler; Wojciech Wozny; Gerhard P. Schwall; Karlfried Groebe; Wolfgang H. Oertel; Patrik Brundin; André Schrattenholz; Günter U. Höglinger

J. Neurochem. (2011) 117, 1066–1074.


Journal of Neuropathology and Experimental Neurology | 2011

Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease.

Candan Depboylu; Martin K.-H. Schäfer; Oscar Arias-Carrión; Wolfgang H. Oertel; Eberhard Weihe; Günter U. Höglinger

Activation of the complement system promotes the removal of pathogens and tissue damage products from the brain and may also be involved in neuronal cell death in neurodegenerative diseases. Here, we analyzed the expression of C1q, the initial recognition subcomponent of the classic complement cascade, in the substantia nigra pars compacta (SNc) in Parkinson disease (PD) and control cases using immunohistochemistry and in situ hybridization. Microglia were determined to be the only cells that expressed C1q in the SNc and other brain areas. In the SNc of PD cases, there was increased deposition of extracellular neuromelanin in the parenchyma, resulting from degeneration of dopaminergic neurons. Neuromelanin granules and blebs of degenerated neurons seemed to be opsonized by C1q and phagocytosed by C1q-positive microglia and macrophages in the parenchyma and in the perivascular spaces. Neuromelanin-laden C1q-positive cells were also attached to the luminal surfaces of blood vessels in the SNc in PD. Thus, we present evidence suggesting that microglia are capable of phagocytosing and clearing cellular debris of degenerating neurons from the SNc through a C1q-mediated pathway in PD.


International Archives of Medicine | 2008

Basic mechanisms of rTMS: Implications in Parkinson's disease

Oscar Arias-Carrión

Background Basic and clinical research suggests a potential role for repetitive transcranial magnetic stimulation (rTMS) in the treatment of Parkinsons disease. However, compared to the growing number of clinical studies on its putative therapeutic properties, the studies on the basic mechanisms of rTMS are surprisingly scarce. Results Animal studies have broadened our understanding of how rTMS affects brain circuits and the causal chain in brain-behavior relationships. The observed changes are thought to be to neurotransmitter release, transsynaptic efficiency, signaling pathways and gene transcription. Furthermore, recent studies suggest that rTMS induces neurogenesis, neuronal viability and secretion of neuroprotective molecules. Conclusion The mechanisms underlying the disease-modifying effects of these and related rTMS in animals are the principle subject of the current review. The possible applications for treatment of Parkinsons disease are discussed.


Cns & Neurological Disorders-drug Targets | 2007

Adult Neurogenesis and Parkinsons Disease

Oscar Arias-Carrión; Nils Freundlieb; Wolfgang H. Oertel; Günter U. Höglinger

Parkinsons disease is a neurodegenerative disorder characterized by a progressive neuronal loss affecting preferentially the dopaminergic neurons of the nigrostriatal projection. Transplantation of fetal dopaminergic precursor cells has provided the proof of principle that a cell replacement therapy can ameliorate clinical symptoms in affected patients. Recent years have provided evidence for the existence of neural stem cells with the potential to produce new neurons, particularly of a dopaminergic phenotype, in the adult mammalian brain. Such stem cells have been identified in so called neurogenic brain areas, where neurogenesis is constitutively ongoing, but also in primarily non-neurogenic areas, such as the midbrain and the striatum, where neurogenesis does not occur under normal physiological conditions. We review here presently published evidence to evaluate the concept that endogenous neural stem cells may have the potential to be instrumentalized for a non-invasive cell replacement therapy with autologous neurons to repair the damaged nigrostriatal dopaminergic projection in Parkinsons disease.


Oxidative Medicine and Cellular Longevity | 2015

Sleep Deprivation and Oxidative Stress in Animal Models: A Systematic Review

Gabriel Villafuerte; Adán Miguel-Puga; Eric Murillo Rodríguez; Sergio Machado; Elias Manjarrez; Oscar Arias-Carrión

Because the function and mechanisms of sleep are partially clear, here we applied a meta-analysis to address the issue whether sleep function includes antioxidative properties in mice and rats. Given the expansion of the knowledge in the sleep field, it is indeed ambitious to describe all mammals, or other animals, in which sleep shows an antioxidant function. However, in this paper we reviewed the current understanding from basic studies in two species to drive the hypothesis that sleep is a dynamic-resting state with antioxidative properties. We performed a systematic review of articles cited in Medline, Scopus, and Web of Science until March 2015 using the following search terms: Sleep or sleep deprivation and oxidative stress, lipid peroxidation, glutathione, nitric oxide, catalase or superoxide dismutase. We found a total of 266 studies. After inclusion and exclusion criteria, 44 articles were included, which are presented and discussed in this study. The complex relationship between sleep duration and oxidative stress is discussed. Further studies should consider molecular and genetic approaches to determine whether disrupted sleep promotes oxidative stress.

Collaboration


Dive into the Oscar Arias-Carrión's collaboration.

Top Co-Authors

Avatar

Sergio Machado

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Antonio Egidio Nardi

Federal Fluminense University

View shared research outputs
Top Co-Authors

Avatar

Flávia Paes

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Ti-Fei Yuan

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Pedro Ribeiro

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Bruna Velasques

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mauricio Cagy

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Silmar Teixeira

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Adriana Cardoso Silva

Federal University of Rio de Janeiro

View shared research outputs
Researchain Logo
Decentralizing Knowledge